Ibogaine by David Dardashti Proposes Medical Off-Ramp for Displaced Kratom Users Amid Global Bans, Urges Expansion of Right to Try Policy

PLAYA DEL CARMEN, Mexico – August 14, 2026 – As expanding state bans and federal enforcement actions sweep across the United States—restricting access to kratom and concentrated 7-hydroxymitragynine (7-OH) extracts—thousands of daily users face acute withdrawal and sudden dependency crises. In response, Ibogaine by David Dardashti has announced specialized treatment protocols designed to serve as a rapid, medical exit strategy.

Rather than steering displaced individuals toward long-term Medication-Assisted Treatment (MAT)—swapping a daily herbal habit for multi-year synthetic opioid dependence—Dardashti’s approach utilizes ibogaine to reset central nervous system receptors. By clearing alkaloid binding sites in a single therapeutic window, the treatment eliminates physical cravings without forcing patients into secondary pharmaceutical dependencies.

To safely process the multi-alkaloid profile unique to kratom, the clinic employs proprietary mathematical modeling software. This system calculates a patient’s total alkaloid exposure against biological variables to determine exact washout periods and customized ibogaine dosing under continuous cardiac monitoring, advancing the treatment from generic application to data-driven precision medicine.

Concurrently, David Dardashti is championing the expansion of “Right to Try” policy frameworks in the United States, advocating for treatment-resistant patients to access regulated ibogaine therapy stateside. This campaign aligns with established medical policies among key U.S. allies:

• New Zealand & South Africa: Recognize ibogaine as a formal medical treatment, classified as a prescription medicine (Schedule 6 in South Africa).

• Canada & Australia: Regulate ibogaine under prescription drug lists and Schedule 4 medical standards, respectively.

• United Kingdom: Controls ibogaine under the Psychoactive Substances Act.

The legal status of kratom across these nations demonstrates an urgent need for synchronized international policy. Australia maintains a strict ban under Schedule 9, the UK prohibits supply via the Psychoactive Substances Act, and Canada forbids sales for internal consumption, whereas New Zealand regulates it by prescription and South Africa leaves it largely unregulated.

Dardashti calls for a comprehensive international allegiance among health authorities to standardize the legal and logistical frameworks surrounding ibogaine treatment. Rather than relying solely on prohibition—which displaces vulnerable populations into illicit markets—a unified coalition could establish standardized medical screening, clinical dosing protocols, and cross-border transport logistics for neuro-restorative care.

“Prohibition without a medically viable off-ramp creates immediate public health emergencies,” states David Dardashti. “By pairing mathematical precision dosing with progressive Right to Try policies, global health leaders can provide a safe, permanent exit strategy for individuals caught in the crossfire of shifting substance regulations.”

About Ibogaine by David Dardashti

Founded in 2010, Ibogaine by David Dardashti is a specialized medical facility offering advanced, data-driven ibogaine treatment protocols for substance dependency and central nervous system recovery. The clinic utilizes proprietary mathematical modeling software to calculate individualized dosing and precise alkaloid washout periods under continuous clinical monitoring. Its core mission is to empower individuals to overcome addiction safely and permanently, providing an effective off-ramp without long-term pharmaceutical reliance. Operating out of Playa del Carmen, Mexico, the center continues to pioneer safe, precision-guided neuro-restorative care for patients worldwide.

Media Contact
Company Name: Ibogaine By David Dardashti
Contact Person: Cole Barressi
Email: Send Email
Country: United States
Website: www.ibogaineclinic.com